

ASX Announcement



Medibio Limited – 1 March 2022

Termination of Underwriting Agreement

Melbourne, Australia and Minneapolis, MN – 1 March 2022: Medibio Limited (“MEB” or “Medibio”) (ASX: MEB) (OTCPINK: MDBIF) refers to its announcement dated 20 January 2022 with regards to the execution of an Underwriting Agreement (“**Agreement**”) with CPS Capital Group Pty Ltd (“**CPS**” or “**Underwriter**”) to partially underwrite its Non-Renounceable Entitlement Offer (“**Entitlement Offer**”) up to \$1 million.

The Company advises that Medibio and CPS have mutually agreed that the Agreement be terminated in light of the escalation of hostilities between Russia and Ukraine.

The Company advises that the Company and CPS will work together on a best endeavors to place any shortfall of the Entitlement Offer in the three month period after the close of the Entitlement Offer.

The Company and its share registry are working towards offering withdrawal rights to those shareholders who have already subscribed to the Entitlement Offer.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

For Further information:

Claude Solitario
Managing Director & CEO
T: +61 3 9692 7222

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.